Toxicity and Activity of Docetaxel in Anthracycline-Pretreated Breast Cancer Patients
Virginia Ferraresi(Cancer Institute (WIA)), F. Cognetti(Sapienza University of Rome), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Angela Vaccaro(Accademia di Belle Arti di Frosinone), Maria Francesca Thorel(Cancer Institute (WIA)), Armando Carpino(Cancer Institute (WIA)), Annelisa Marsella(Cancer Institute (WIA)), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Michèle Milella(National Cancer Institute), A.M. D'Ottavio(Cancer Institute (WIA)), E. Terzoli(Catholic University of America)
Cited by 36
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k